Tianzhu Lu1, Xingyun Xie1, Qiaojuan Guo1,2,3, Shenghua Zhan1,2,3, Cheng Lin1, Shaojun Lin1,2,3, Yu Zhang1,2,3, Jingfeng Zong1,2,3, Jianji Pan1,2,3. 1. Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fuzhou, China. 2. Department of Radiation Oncology, Fujian Cancer Hospital, Fuzhou, China. 3. Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fujian Medical University Cancer Hospital, Fuzhou, China.
Abstract
BACKGROUND: It was reported that reduced radiotherapy is feasible for children with nasopharyngeal carcinoma (NPC) and papilloma virus-positive oropharyngeal cancer. Therefore, we performed this study to explore the prognosis of reduced-dose radiation in adult with NPC. METHODS: Between 2004 and 2013, we retrospectively analyzed 19 patients histologically diagnosed with NPC, who received <66 Gy radiation therapy. Ten patients receiving <54 Gy to the primary site were group A. Nine patients receiving ≥54 Gy were group B. RESULTS: Thirteen patients received induction chemotherapy (IC) for two or three cycles. In group A, the 5-year overall survival (OS) was 50.0%. For group B, the 5-year OS, locoregional relapse-free survival, progression-free survival, and distant metastasis-free survival were 88.9%, 100.0%, 88.9%, and 88.9%. Group B had a better prognosis than group A on OS (88.9% vs 50.0%, P = .03). CONCLUSION: Patients receiving ≥54 Gy but <66 Gy with IC achieved good local control and long-term survival.
BACKGROUND: It was reported that reduced radiotherapy is feasible for children with nasopharyngeal carcinoma (NPC) and papilloma virus-positive oropharyngeal cancer. Therefore, we performed this study to explore the prognosis of reduced-dose radiation in adult with NPC. METHODS: Between 2004 and 2013, we retrospectively analyzed 19 patients histologically diagnosed with NPC, who received <66 Gy radiation therapy. Ten patients receiving <54 Gy to the primary site were group A. Nine patients receiving ≥54 Gy were group B. RESULTS: Thirteen patients received induction chemotherapy (IC) for two or three cycles. In group A, the 5-year overall survival (OS) was 50.0%. For group B, the 5-year OS, locoregional relapse-free survival, progression-free survival, and distant metastasis-free survival were 88.9%, 100.0%, 88.9%, and 88.9%. Group B had a better prognosis than group A on OS (88.9% vs 50.0%, P = .03). CONCLUSION:Patients receiving ≥54 Gy but <66 Gy with IC achieved good local control and long-term survival.